

MAR 06 2009

Application Serial No. 10/522,110  
 Reply to final office action of December 23, 2008

PATENT  
 Docket: CU-4057

Amendments To The Claims


The listing of claims presented below will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (currently amended) A compound of riboflavin derivatives selected from the group consisting of which is 5'-lauric acid monester of riboflavin, isobutyrate of riboflavin, riboflavin-2,6-dimethoxybenzoate, and adamantane acid ester of riboflavin.

2- 5 (canceled)

6. (currently amended) An oil suspension preparation using the compound of claim 4 comprising as a main active constituent being mainly composed of ethyl oleate and the compound of claim 1 in Formula II:



Formula II.

7. (currently amended) The suspension preparation according to claim 6, wherein camellia oil is added and the ratio of weight and volume of each ingredient are as follows:

Compound of Formula II 50 - 150 mg.

Application Serial No. 10/522,110  
 Reply to final office action of December 23, 2008

PATENT  
 Docket: CU-4057


Ethyl oleate	0.1 - 1 ml, <u>and</u>
Camellia oil	0-1 ml.

8. (currently amended) The suspension preparation according to claim 7, wherein the preferable ratio of weight and volume of each ingredient are as follows:

Compound of Formula II	150 mg,
Ethyl oleate	0.5 ml, <u>and</u>
Camellia oil	0.5 ml.

9-11. (canceled)

12. (previously presented) A method of using therapeutically treating either an arboflavinosis condition, a digestive tract catarrh, or a persistent oral ulcer of an animal a compound of claim 1, comprising the steps of: using a obtaining a suspension preparation containing the compound to treat a disease a main active constituent being mainly composed of ethyl oleate and the compound of Formula II:



Formula II; and  
administering a portion of the suspension preparation to the animal.

13-20. (canceled)

Application Serial No. 10/522,110  
Reply to final office action of December 23, 2008

PATENT  
Docket: CU-4057

- 21. (new) The method of claim 12 further comprising the step of: subjecting the animal to a chemotherapy regimen.**
- 22. (new) The method of claim 21 wherein the chemotherapy regimen is selected from the group consisting of high-dose methotrexate (HDMTX) chemotherapy, and DA (daunorubicin, cytosine arabinoside) chemotherapy.**
- 22. (new) The method of claim 12 wherein the administering step comprises injecting the portion of the suspension preparation into the animal.**
- 23. (new) The method of claim 12 wherein the administering step comprises injecting intermuscularly the portion of the suspension preparation into the animal.**
- 24. (new) The method of claim 12 wherein the administering step comprises feeding the portion of the suspension preparation to the animal.**
- 25. (new) The method of claim 12, wherein the suspension preparation is used to treat the ariboflavinosis condition.**
- 26. (new) The method of claim 12, wherein the suspension preparation is used to treat digestive tract catarrh caused by bone marrow transplantation, leukemia or chemotherapy.**
- 27. (new) The method of claim 12, wherein the suspension preparation is used to treat persistent oral ulcer.**
- 28. (new) The method of claim 12, wherein the animal is a rat.**

Application Serial No. 10/522,110  
Reply to final office action of December 23, 2008

PATENT  
Docket: CU-4057

**29. (new) The method of claim 12, wherein the animal is a human.**

**30. (new) The method of claim 12, wherein the suspension preparation further contains camellia oil.**

**31. (new) The method of claim 29, wherein the suspension preparation is combined with relative ranges of weights and volumes of each ingredient as follows:**

**Compound of Formula II 50 - 150 mg;**  
**Ethyl oleate 0.1 - 1 ml; and**  
**Camellia oil 0-1 ml.**

**32. (new) The method of using the compound of claim 31, wherein the suspension preparation is combined with relative ranges of weights and volumes of each ingredient as follows:**

**Compound of Formula II 150 mg,**  
**Ethyl oleate 0.5 ml, and**  
**Camellia oil 0.5 ml.**